Core Insights - Elutia Inc. has been selected to exhibit its EluPro™ Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange, highlighting its innovative approach in healthcare technology [1][4] - The EluPro is the first FDA-cleared antibiotic-eluting bioenvelope specifically designed for cardiac implantable electronic devices (CIEDs) and neurostimulators, combining a natural biologic scaffold with antibiotics for enhanced patient outcomes [3][4] Company Overview - Elutia develops and commercializes drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients, with a mission to humanize medicine [6] Product Details - The EluPro BioEnvelope promotes healthy tissue regeneration while providing antimicrobial protection directly at the surgical site, enhancing procedural efficiency and standard of care [3][4] - The product is designed to address critical post-surgical complications such as infection, migration, and erosion, thereby improving patient safety and delivering clinical and economic value [4] Event Significance - The Vizient Innovative Technology Exchange provides a platform for suppliers to showcase products that improve clinical outcomes and healthcare delivery, with Elutia's participation underscoring its commitment to innovation in the healthcare sector [2][4] - Since 2003, Vizient has reviewed over 1,700 product submissions as part of its Innovative Technology Program, indicating a rigorous selection process for showcasing impactful healthcare technologies [4]
Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange